< Terug naar vorige pagina
Onderzoeker
Tim Muilwijk
- Disciplines:Urologie en nefrologie
Affiliaties
- Urogenitale, Abdominale en Plastische Chirurgie (Afdeling)
Lid
Vanaf1 jan 2019 → 12 jul 2022 - Vrouw en Kind (Afdeling)
Lid
Vanaf1 aug 2017 → 31 dec 2018
Publicaties
1 - 10 van 35
- Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results from an Embedded Belgian Multicenter Prospective Registry(2023)
Auteurs: Tim Muilwijk, Murat Akand, Ben Van Cleynenbreugel, Steven Joniau, Frank Van der Aa
Pagina's: 422 - 430 - Radiological features characterising indeterminate testes masses: a systematic review and meta-analysis(2023)
Auteurs: Tim Muilwijk
Pagina's: 288 - 300 - Optimizing treatment and follow-up of patients with bladder cancer: risk stratification and biomarkers(2022)
Auteurs: Tim Muilwijk, Steven Joniau, Maarten Albersen, Thomas Gevaert
- Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study(2022)
Auteurs: Tim Muilwijk, Steven Joniau
Pagina's: 491 - 497 - Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study(2021)
Auteurs: Tim Muilwijk, Steven Joniau
Pagina's: 507 - 515 - Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer(2021)
Auteurs: Tim Muilwijk, Murat Akand, Loic Baekelandt, Frank Van der Aa, Steven Joniau
- Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer(2021)
Auteurs: Tim Muilwijk, Murat Akand, Frank Van der Aa, Louis Libbrecht, Steven Joniau
Pagina's: 7890 - 7900 - Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021(2021)
Auteurs: Tim Muilwijk
Pagina's: 4 - 6 - Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes(2021)
Auteurs: Tim Muilwijk, Steven Joniau
Pagina's: 2545 - 2552 - Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma(2021)
Auteurs: Tim Muilwijk
Pagina's: 2567 - 2577